Press Releases Latest Oct 13, 2021 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update Press Releases Year None202120202019201820172016201520142013 Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option Jan 15, 2021 Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering Of Units Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) Jan 07, 2021 Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities Dec 08, 2020 Theratechnologies Announces New Findings For Its Lead Investigational Compound TH1902 For The Treatment Of Several Additional Cancers Nov 23, 2020 Theratechnologies To Present At The Piper Sandler Virtual Healthcare Conference Nov 16, 2020 Theratechnologies Announces Data From Oral Presentation At AASLD Showing How Tesamorelin Can Reduce Fibrosis And NASH First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 31 - 40 of 262
Oct 13, 2021 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update
Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers
Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Jan 15, 2021 Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
Jan 07, 2021 Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities
Dec 08, 2020 Theratechnologies Announces New Findings For Its Lead Investigational Compound TH1902 For The Treatment Of Several Additional Cancers
Nov 16, 2020 Theratechnologies Announces Data From Oral Presentation At AASLD Showing How Tesamorelin Can Reduce Fibrosis And NASH
